# A Reduced Toxicity Allogeneic Unrelated Donor Stem Cell Transplantation (SCT) for Severe Sickle Cell Disease

> **NCT01279616** · PHASE2 · TERMINATED · sponsor: **Nationwide Children's Hospital** · enrollment: 8 (actual)

## Conditions studied

- Sickle Cell Disease

## Interventions

- **DRUG:** Fludarabine monophosphate
- **DRUG:** Rituximab
- **DRUG:** Busulfan
- **DRUG:** ATG
- **DRUG:** Cyclophosphamide
- **DRUG:** Mycophenolate mofetil
- **DRUG:** Tacrolimus

## Key facts

- **NCT ID:** NCT01279616
- **Lead sponsor:** Nationwide Children's Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2010-09
- **Primary completion:** 2015-01
- **Final completion:** 2015-01
- **Target enrollment:** 8 (ACTUAL)
- **Why stopped:** PI moving to a different institution.
- **Last updated:** 2019-04-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01279616

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01279616, "A Reduced Toxicity Allogeneic Unrelated Donor Stem Cell Transplantation (SCT) for Severe Sickle Cell Disease". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT01279616. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*